Aug 2026· Frontiers in Neurology· Vol 17· 0 citations· 71 references
Medicine
TL;DR
It is argued that stage-specific, multimodal composites, integrated through harmonized international cohorts and machine learning, offer the most credible path to prognostic enrichment and to shorter, adequately powered, and preventive trials.
Abstract
Progressive cerebellar ataxias, including the polyglutamine spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6), Friedreich ataxia, and the autosomal recessive and sporadic forms, are rare, clinically heterogeneous neurodegenerative disorders. Disease-modifying therapies, notably antisense oligonucleotides and the approved compound omaveloxolone, are now entering or reaching the clinic, which makes reliable prediction of disease progression a central obstacle to trial success. Rarity, slow and variable decline, and a quantifiable premanifest window together demand sensitive, validated tools to forecast who will progress, how fast, and when symptoms begin. This review synthesizes evidence across five complementary biomarker domains, clinical, imaging, fluid, genetic, and digital, and judges their readiness for forecasting onset and progression. Clinical scales such as SARA capture genotype-specific trajectories but lose sensitivity at the extremes of the disease course. Volumetric, microstructural, and spectroscopic MRI and blood neurofilament light chain change before ataxia onset and predict subsequent decline, whereas repeat length and genetic modifiers set prior risk. Wearable-sensor gait and balance metrics detect change earlier than clinical scales and sharply reduce required sample sizes. We argue that no single modality satisfies every context of use, and that stage-specific, multimodal composites, integrated through harmonized international cohorts and machine learning, offer the most credible path to prognostic enrichment and to shorter, adequately powered, and preventive trials.
Disease progression in SCA27B is characterised by mild progression, ageing-related motor variabilities and comorbidities, and associated with repeat size on both alleles, and associated with repeat size on both alleles.
A. Traschütz, Ralf-Dieter Hilgers, F. Erdlenbruch et al.· EBioMedicine· 0 citations
Hereditary cerebellar ataxias comprise a heterogeneous group of neurodegenerative disorders with overlapping clinical manifestations, often making accurate bedside diagnosis challenging. Careful clinical phenotyping remains essential to guide targeted genetic testing, particularly in resource limited settings. We retro...
Khyati S. Patel, Nehal M. Shah· International Journal of Res...· 0 citations
The genetics, epidemiology, clinical spectrum, imaging findings, differential diagnosis, and management of SCA27B are reviewed, and routine FGF14 testing in patients with unexplained late-onset ataxia, downbeat nystagmus, or episodic cerebellar symptoms is supported.
Anish Mehta, Sharvani Gowtham, I. S. M. Giridhar et al.· Annals of Movement Disorders· 0 citations
Frontotemporal dementia (FTD) is a clinically and genetically diverse group of neurodegenerative disorders predominantly affecting the frontal and anterior temporal lobes, leading to progressive changes in behavior, language, and executive function. FTD is the most common cause of young-onset dementia and third overall...
Piotr Wilczkowski, Aleksandra Palka, Natalia Krzysztofek et al.· International Journal of Inn...· 0 citations
Neuroinflammation is a critical pathological feature underlying neurodegenerative diseases. Spinocerebellar ataxia 13 (SCA13) is a heterogeneous ataxia with several allelic variations of differing phenotypes. All are neurodegenerative and currently without effective treatment. Our prior work identified human
KCNC3...
Jun-Xiang Yin, Michael Wu, Jennifer White et al.· Acta Neuropathologica Commun...· 0 citations
UBTF-related CONDBA presents with early normal or mildly delayed development followed by regression and progressive ataxia, and elevated NFL may serve as a biomarker of neuronal injury in both humans and animal models.
A. Nagy, A. Luddy, Francine Molay et al.· Journal of Medical Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.